Japanese Pharmaceutical Market & Registration Strategies- Part 2
The second article in the series focuses on strategies for success in registering products on the Japanese market.
November 12, 2024
by Deepak Hegde
Japanese Pharmaceutical Market & Registration Strategies – Part 1
The article provides an outline of characteristics、Regulatory bodies、 Pricing、Reimbursement、the process of registering an innovative drug and generic drugs in Japan.
November 12, 2024
by Deepak Hegde
Quality Sourcing Opportunities at 2022 Zhejiang Export Commodity Online Fair “Japan & Republic of Korea Station – APIs session”!
The 2022 Zhejiang Export Commodity Online Fair (Pharma Sector) is coming with a new session. The portals for the “Japan & Republic of Korea Station - APIs session” is now launched to welcome the participation of both pharmaceutical suppliers located in Zh
May 9, 2022
by PharmaSources.com
Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19
Roche announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Ronapreve™ (casirivimab and imdevimab), for the treatment of patients with mild to moderate COVID-19 via intravenous infusion.
July 26, 2021
by worldpharmanews
Japan First to Approve Roche’s Ronapreve to Treat COVID-19
Roche received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Ronapreve (casirivimab and imdevimab), for the treatment of mild to moderate COVID-19 via intravenous infusion.
July 22, 2021
by contractpharma
A Drop for Clear Vision: Japan Has Surpassed Itself Again with the Development of Ultra-High-Concentration Lutein
According to the World Report on Vision published in 2020 by World Health Organization (WHO), the incidence of most eye diseases and visual impairments varies by age, area of residence, and income level.
July 14, 2021
by prnasia
AstraZeneca COVID-19 Vaccine Vaxzevria Authorized for Emergency Use in Japan
AstraZeneca’s COVID-19 vaccine, Vaxzevria, has been granted special approval for emergency use in Japan for active immunization of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2.
May 24, 2021
by americanpharmaceuticalreview
Moderna might manufacture COVID-19 vaccines in Japan
Moderna Inc is considering manufacturing its COVID-19 vaccine in Japan, Nikkei newspaper reported, citing an interview with Stephane Bancel, the company’s CEO.
May 24, 2021
by expresspharma
New Pathway Launched for Pioneering Life Science Companies Seeking Japanese Market Entry
Today, pioneering life science organizations seeking to navigate Japanese market entry gained a new pathway. Shonan Health Innovation Park ("Shonan iPark", Kanagawa Prefecture, Japan) announced new membership offerings for innovation and ...
April 16, 2021
by prnasia
Takeda sells Japan’s non-core products portfolio to Teijin Pharma
Takeda Pharmaceutical has completed the asset transfer linked to a portfolio of select non-core products in Japan to Teijin Pharma for $1.25bn (JPY133bn).
April 2, 2021
by pharmaceutical-technology
Takeda submits New Drug Application for lanadelumab in Japan
Japan-based, R&D-driven Takeda Pharmaceutical Company Limited has submitted a New Drug Application (NDA) for lanadelumab to the Ministry of Health, Labour and Welfare (MHLW) in Japan.
March 18, 2021
by pharmaceutical-business-review
Japan Health Ministry finds new coronavirus variant
The variant was identified in airport tests on a man in his 40s, a woman in her 30s and two teens, the ministry said.
January 12, 2021
by expresspharma